Protocols
Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE
Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLAStine and Dacarbazine
Treatment for Adjuvant Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin
Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)
Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma Using Pegaspargase, Methotrexate and Dexamethasone
Treatment of Non-Hodgkin Lymphoma with Bendamustine
Treatment of Non-Hodgkin Lymphoma with Bendamustine and riTUXimab
Consolidation Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin
Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin
Summary for Topical Carmustine in Cutaneous T-cell Lymphoma
Treatment of Hairy Cell Leukemia with Cladribine
Therapy for Low Grade Lymphoma and Chronic Lymphocytic Leukemia Using Chlorambucil
Treatment of Indolent B-cell Lymphoma Chlorambucil and riTUXimab
Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine and predniSONE
Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab
Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and RiTUXimab in Diffuse Large B-cell Lymphoma
Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) with Bendamustine
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and riTUXimab
Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and riTUXimab
Treatment of relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab (CVP-R)
Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and riTUXimab
Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and riTUXimab
Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRIStine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab
Cyclosporine for cytopenias associated with lymphoproliferative disorder of large granular lymphocytes
Treatment of Advanced indolent lymphoma using Cyclophosphamide, vinCRIStine and predniSONE
Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLAStine, Procarbazine and predniSONE
Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab (CVP-R)
Therapy of Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia or Multiple Myeloma Using Cyclophosphamide
Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, vinCRIStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate
Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab
Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRUtinib
Treatment of Low-Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine
Treatment of Relapsed Indolent Lymphoma with Fludarabine and riTUXimab
Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin (GDP)
Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin (GDP) with riTUXimab
Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and riTUXimab
Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate
Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High Dose Methotrexate
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Ibrutinib
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Using Idelalisib and riTUXimab
Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine
Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab
Topical Mechlorethamine in Cutaneous T-cell Lymphoma
Treatment for refractory cutaneous T-cell lymphoma using Bexarotene (Note: approval from the Health Canada Special Access Programme required)
Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis
Treatment of Relapsed/Refractory Mantle-Cell Lymphoma Using iBRUtinib
Treatment of Relapsed or Refractory Hodgkin Lymphoma Using Nivolumab Protocol
Treatment of Relapsed or Refractory Hodgkin Lymphoma Using 4-Weekly Nivolumab
Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with oBINutuzumab and Chlorambucil
Treatment of riTUXimab-refractory Follicular Lymphoma (FL) with oBINutuzumab in combination with Bendamustine
Lymphoma Palliative Chemotherapy
Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin’s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab
Treatment of Lymphoma with single agent riTUXimab
Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for Ibritumomab 90Y (ZEVALIN®)
Maintenance riTUXimab for Indolent Lymphoma
Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with romiDEPsin
Treatment of Multicentric Castleman’s Disease (MCD) Negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus – 8 (HHV-8) Using Siltuximab
Treatment of Natural Killer or T-Cell Lymphoma Using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and riTUXimab
Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide, CISplatin and Dexamethasone
Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality
Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant
Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide
Therapy of Multiple Myeloma Using Carfilzomib and Dexamethasone With or Without Cyclophosphamide
Therapy of Multiple Myeloma Using Carfilzomib, Lenalidomide with Dexamethasone
Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone With or Without Cyclophosphamide
Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone
Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant
Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone
Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone
Maintenance Therapy of Multiple Myeloma Using Lenalidomide
Treatment of Multiple Myeloma Using Melphalan and predniSONE
Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan
Treatment of Multiple Myeloma with Pamidronate
Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone
Treatment of Multiple Myeloma with Zoledronic Acid
